Home/Investors/Public shareholders via Hong Kong Stock Exchange

Public shareholders via Hong Kong Stock Exchange

Biotech Investor · 2 portfolio companies

Portfolio
2
Combined Value
$208.8B
Focus Areas
8
Top Stage
Commercial

Portfolio Companies

CompanyValuation
Hansoh Pharma$191.6B
WuXi Biologics$17.2B